Neurizon Therapeutics Ltd (ASX: NUZ) Share Price and News

Dr Thurn brings experience in drug discovery, development, regulation and commercialisation, acquired through leadership roles in research organisations and industry, including early-stage, fastgrowing, private and publicly listed biotechnology companies. His previous responsibilities have included leading a variety of US Food and Drug Administration (FDA) Investigational New Drug (IND) applications across a range of therapeutic areas and the evaluation of drugs and vaccines for registration in Australia as a part of the Drug Safety Evaluation Branch (DSEB) of the Therapeutics Goods Administration (TGA). Michael has also been responsible for the execution of Phase 1 and 2 clinical trials and business development activities across animal and human health products. He possesses entrepreneurial, leadership and management skills that have seen him achieve results over a 25-year career in the biotechnology industry, including co-founding MARP Therapeutics and roles with Botanix Pharmaceuticals (ASX:BOT), Mimetica, Spinifex Pharmaceuticals, Cytopia, Xenome and Novogen. During this time, Dr Thurn has gained Australian and US capital markets exposure and has accessed funding through private and public channels, partnerships, and non-dilutive means.

Dr MacFarlane has over 30 years of experience in the development and commercialisation of pharmaceutical products and devices. She is the Founder and President of SmartPharma, a commercial and strategic consulting firm that specialises in market and product assessments, market sizing and forecasting, pre-launch preparation and launch and marketing of pharmaceutical products for biopharmaceutical companies. Katie also currently is the Head of Commercial for Arkayli Biopharma, a startup developing a treatment for a rare pediatric disease. Previously, she was Chief Commercial Officer at Agile Therapeutics, Vice President of Marketing, Sales and New Product Planning at Warner Chilcott, and Senior Director of Marketing at Parke-Davis (now Pfizer). Dr MacFarlane is a member of the Board of Directors of Mayne Pharmaceuticals, an affiliate faculty member of the Purdue University School of Pharmacy and a Founding Member and Advisor to IPhO. She previously served on the Board of Directors for RespireRx and a nonprofit, INMED Partnerships for Children.

Mr Duchini brings board-level experience with expertise spanning professional services, life sciences, biotechnology, banking, finance, and the not-for profit sector. His background includes roles such as Chair, Executive and Non-Executive Board Director, Risk & Audit Committee Chair, and Chief Strategy Officer. Additionally, he holds the position of Chair at Lymphoma Australia, a not-for-profit organization supporting lymphoma patients and their caregivers in Australia. Mr Duchini has been appointed as a member of the Research and Development Tax Incentive Committee that works to advise Innovation and Science Australia on the operation and impact of the R&DTI in Australia and Member of Medicines Australia Advisory Council. The role of the Medicines Australia Council is to support the Medicines Australia Board's role in shaping strategy and maintaining appropriate continuity of direction. The council is future-focused and provides the board with advice on trends and issues impacting the pharmaceutical industry in the medium to long term. Mr Duchini has previously sat on the AusBiotech Board of Directors for nine years, where he played a role in the development of two national life science industry strategies. He also served as a Board Director at Deloitte Australia, overseeing the governance, strategy development, and stewardship of the partnership with annual revenues of $2.2 billion. Mr Duchini's executive experience includes 23 years at Deloitte Australia where he held positions as an equity partner, including 8 years on the Deloitte Australia Board. He advised Australian and international groups to manage their investments in R&D nationally and internationally, developed and executed the national tax strategy, and led senior cross-disciplinary teams serving prominent clients such as National Australia Bank, ANZ Bank, and Australia Post.

Mr Hughes brings more than 20 years of experience with listed companies. He possesses corporate finance experience, having led project financing and capital raisings in the industrial sector. He has held managerial, tax and finance roles with multinational companies including Lend Lease, Fortescue Metals and Rio Tinto.

-

-

-

-